Similar articles

• [Blood pressure lowering by the ACE-inhibitor spirapril. "24-hour efficacy of real once daily application of spirapril (HERAS study)"].

  Düsing R, Müller U. Düsing R, et al. MMW Fortschr Med. 2003 Oct 9;145 Suppl 3:77-80. MMW Fortschr Med. 2003. PMID: 15490771 Clinical Trial. German.
• Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?

  van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ, Ritsema van Eck HJ, Boomsma F, Derkx FH, Schalekamp MA. van den Meiracker AH, et al. J Hypertens. 1992 Aug;10(8):803-12. J Hypertens. 1992. PMID: 1325513 Clinical Trial.
• Placebo-controlled crossover comparison of spirapril at 3, 6, 12 and 24 mg once daily in mild to severe essential hypertension.

  Guitard C, Sassano P, Tzincoca C, Duchiez J, Safar ME. Guitard C, et al. Blood Press Suppl. 1994;2:61-8. Blood Press Suppl. 1994. PMID: 8061848 Clinical Trial.
• Efficacy and safety of spirapril in mild-to-moderate hypertension.

  Hayduk K, Kraul H. Hayduk K, et al. J Cardiovasc Pharmacol. 1999 Aug;34 Suppl 1:S19-23. doi: 10.1097/00005344-199908001-00004. J Cardiovasc Pharmacol. 1999. PMID: 10499560 Review.
• Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.

  Noble S, Sorkin EM. Noble S, et al. Drugs. 1995 May;49(5):750-66. doi: 10.2165/00003495-199549050-00008. Drugs. 1995. PMID: 7601014 Review.